Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.48 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.48 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6705632 | 1.00 | FAAH (0.53) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL6705927 | 1.00 | FAAH (0.53) | FAAHMEN1KMT2AMAPK1DNM1 | |
| Hydrochloric Acid SCHEMBL432397 | 0.98 | FAAH (0.51) | FAAHMEN1KMT2AMAPK1DNM1 | |
| Acetic Acid SCHEMBL1987400 | 0.96 | FAAH (0.49) | FAAHMEN1KMT2AMAPK1DNM1 | |
| Acetic Acid SCHEMBL428009 | 0.96 | FAAH (0.49) | FAAHMEN1KMT2AMAPK1DNM1 | |
| Acetic Acid SCHEMBL451414 | 0.96 | FAAH (0.49) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL16011427 | 0.88 | FAAH (0.66) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL15007547 | 0.88 | FAAH (0.66) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL15007772 | 0.88 | FAAH (0.66) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL16011423 | 0.88 | FAAH (0.66) | FAAHMEN1KMT2AMAPK1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016110872-A1 | FOOT CARE COMPOSITIONS | Zydus Wellness Limited (IN) | 2016-07-14 | — | — | WO | disclosed |
| EP-2419077-A2 | PROCESS OF TREATING DAMAGED HAIR | Rhodia Opérations (FR) | 2012-02-22 | — | — | EP | disclosed |
| EP-2337544-A2 | USE OF MATRIX METALLOPROTEINASE INHIBITORS IN SKIN CARE | Living Proof, Inc. (US) | 2011-06-29 | — | — | EP | disclosed |
| WO-2010089228-A9 | AQUEOUS COMPOSITION SUITABLE AS SHAMPOO | RHODIA OPERATIONS (FR) | 2011-04-21 | — | — | WO | disclosed |
| WO-2010118925-A2 | PROCESS OF TREATING DAMAGED HAIR | RHODIA OPERATIONS (FR) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010089228-A1 | AQUEOUS COMPOSITION SUITABLE AS SHAMPOO | RHODIA OPERATIONS (FR) | 2010-08-12 | — | — | WO | disclosed |
| EP-2216010-A1 | Aqueous composition suitable as shampoo | Rhodia Opérations (FR) | 2010-08-11 | — | — | EP | disclosed |
| EP-1285647-B1 | Hair cosmetic comprising guanidine derivative and N-alpha-acylarginine | AJINOMOTO KK (JP) | 2010-08-04 | — | — | EP | disclosed |
| US-20090068255-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS IN SKIN CARE | LIVING PROOF, INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2008134712-A2 | USE OF MATRIX METALLOPROTEINASE INHIBITORS IN SKIN CARE | LIVING PROOF, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008070368-A2 | METHODS AND COMPOSITIONS FOR SKIN CARE | LIVING PROOF, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| EP-1285579-B1 | Bactericidal guanidine derivatives, dermally applicable composition, washing composition, and antibacterial fibre aggregate | AJINOMOTO KK (JP) | 2005-11-02 | — | — | EP | disclosed |
| US-20040092599-A1 | Production process of guanidine derivative containing amido group and salt thereof | AJINOMOTO CO., INC. (JP) | 2004-05-13 | — | — | US | disclosed |
| US-20030162838-A1 | Bactericide, antiseptic, dermally applicable composition, washing composition, antibacterial fiber aggregate, method for eradicating a microorganism, and method for inhibiting the proliferation of a microorgamism | AJINOMOTO CO., INC. (JP) | 2003-08-28 | — | — | US | disclosed |
| US-20030108508-A1 | Hair rinsing, conditioning, setting | AJINOMOTO CO., INC (JP) | 2003-06-12 | — | — | US | disclosed |
| EP-1285579-A1 | Bactericidal guanidine derivatives, dermally applicable composition, washing composition, and antibacterial fibre aggregate | Ajinomoto Co., Inc. (JP) | 2003-02-26 | — | — | EP | disclosed |
| EP-1285647-A2 | Hair cosmetic comprising guanidine derivative and N-alpha-acylarginine | Ajinomoto Co., Inc. (JP) | 2003-02-26 | — | — | EP | disclosed |
| EP-1270552-A2 | Production process for a guanidine derivative containing an amido group and for a salt thereof | Ajinomoto Co., Inc. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090068255-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS IN SKIN CARE | MMP1, MMP9, MMP17 | FAAH 970/4885MEN1 1603/4885KMT2A 2537/4885 |
| US-20030162838-A1 | Bactericide, antiseptic, dermally applicable composition, washing composition, antibacterial fiber aggregate, method for eradicating a microorganism, and method for inhibiting the proliferation of a microorgamism | ARG1, ALKBH1, GANC | FAAH 682/4885MEN1 4176/4885KMT2A 4271/4885 |
| US-20040092599-A1 | Production process of guanidine derivative containing amido group and salt thereof | FASN, GMPS, CEL | FAAH 278/4885MEN1 4444/4885KMT2A 2406/4885 |
| US-20030108508-A1 | Hair rinsing, conditioning, setting | PRMT1, ARG1, PRMT5 | FAAH 584/4885MEN1 1340/4885KMT2A 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.